At the recent Radiological Society of North America annual meeting, Hologic presented its tomosynthesis technology, including a dedicated prone biopsy system with 2D or 3D imaging. This is the first time the company has made the Affirm prone breast biopsy system—a system that’s upgradeable to allow for 3D imaging-guided breast biopsies—for display since securing FDA clearance this year.

Clinicians have added confidence with the platform’s high-quality imaging, 3D biopsy capability, and expedited workflow, in addition to 360° access to the breast. Early clinical and patient feedback has been positive. In fact, more than 95% of patients described the procedure as faster, more comfortable, and less painful than expected.

Further, the company’s Genius 3D mammography exam, which is only available on the Selenia Dimensions system, has been shown to reduce recall rates and increase invasive cancer detection, while discovering invasive cancer earlier, according to recent studies.

At RSNA, the company also highlighted its low-dose 3D mammography exams with C-View software, which translate to less time under compression—and that increases patient comfort at a lower radiation dose. Also launched was the Affirm lateral arm biopsy accessory, which enables physicians to target challenging lesions with confidence, in addition to successful biopsies of thinly compressed breasts.

“As the only manufacturer with a core focus on innovating and advancing breast health, we are committed to introducing new products, like the Affirm prone system, that offer unique patient and user benefits and address workflow challenges, enhancing the overall healthcare experience,” says Pete Valenti, division president of breast and skeletal health solutions at Hologic.

For more information about this technology, visit Hologic.